Valdagni Riccardo, Rancati Tiziana, Ghilotti Marco, Cozzarini Cesare, Vavassori Vittorio, Fellin Gianni, Fiorino Claudio, Girelli Giuseppe, Barra Salvina, Zaffaroni Nadia, Pierotti Marco Alessandro, Gariboldi Manuela
Prostate Program, Fondazione IRCCS-Istituto Nazionale dei Tumori, Milano, Italy.
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1431-40. doi: 10.1016/j.ijrobp.2008.10.021. Epub 2009 Feb 11.
The main purpose of this work was to try to elucidate why, despite excellent rectal dose-volume histograms (DVHs), some patients treated for prostate cancer exhibit late rectal bleeding (LRB) and others with poor DVHs do not. Thirty-five genes involved in DNA repair/radiation response were analyzed in patients accrued in the AIROPROS 0101 trial, which investigated the correlation between LRB and dosimetric parameters.
Thirty patients undergoing conformal radiotherapy with prescription doses higher than 70 Gy (minimum follow-up, 48 months) were selected: 10 patients in the low-risk group (rectal DVH with the percent volume of rectum receiving more than 70 Gy [V70Gy] < 20% and the percent volume of rectum receiving more than 50 Gy [V50Gy] < 55%) with Grade 2 or Grade 3 (G2-G3) LRB, 10 patients in the high-risk group (V70Gy > 25% and V50Gy > 60%) with G2-G3 LRB, and 10 patients in the high-risk group with no toxicity. Quantitative reverse-transcriptase polymerase chain reaction was performed on RNA from lymphoblastoid cell lines obtained from Epstein-Barr virus-immortalized peripheral-blood mononucleated cells and on peripheral blood mononucleated cells. Interexpression levels were compared by using the Kruskal-Wallis test.
Intergroup comparison showed many constitutive differences: nine genes were significantly down-regulated in the low-risk bleeder group vs. the high-risk bleeder and high-risk nonbleeder groups: AKR1B1 (p = 0.019), BAZ1B (p = 0.042), LSM7 (p = 0.0016), MRPL23 (p = 0.015), NUDT1 (p = 0.0031), PSMB4 (p = 0.079), PSMD1 (p = 0.062), SEC22L1 (p = 0.040), and UBB (p = 0.018). Four genes were significantly upregulated in the high-risk nonbleeder group than in the other groups: DDX17 (p = 0.048), DRAP1 (p = 0.0025), RAD23 (p = 0.015), and SRF (p = 0.024). For most of these genes, it was possible to establish a cut-off value that correctly classified most patients.
The predictive value of sensitivity and resistance to LRB of the genes identified by the study is promising and should be tested in a larger data set.
本研究的主要目的是试图阐明为何尽管一些前列腺癌患者的直肠剂量体积直方图(DVH)表现出色,但仍出现晚期直肠出血(LRB),而另一些DVH较差的患者却未出现。在AIROPROS 0101试验纳入的患者中分析了35个参与DNA修复/辐射反应的基因,该试验研究了LRB与剂量学参数之间的相关性。
选择30例接受适形放疗且处方剂量高于70 Gy(最短随访48个月)的患者:10例低风险组患者(直肠DVH显示接受超过70 Gy[V70Gy]<20%且接受超过50 Gy[V50Gy]<55%的直肠体积百分比)出现2级或3级(G2 - G3)LRB,10例高风险组患者(V70Gy>25%且V50Gy>60%)出现G2 - G3 LRB,以及10例高风险组无毒性的患者。对从爱泼斯坦 - 巴尔病毒永生化外周血单核细胞获得的淋巴母细胞系RNA以及外周血单核细胞进行定量逆转录聚合酶链反应。使用Kruskal - Wallis检验比较基因表达水平。
组间比较显示出许多组成性差异:与高风险出血组和高风险无出血组相比,低风险出血组中有9个基因显著下调:AKR1B1(p = 0.019)、BAZ1B(p = 0.042)、LSM7(p = 0.0016)、MRPL23(p = 0.015)、NUDT1(p = 0.0031)、PSMB4(p = 0.079)、PSMD1(p = 0.062)、SEC22L1(p = 0.040)和UBB(p = 0.018)。与其他组相比,高风险无出血组中有4个基因显著上调:DDX17(p = 0.048)、DRAP1(p = 0.0025)、RAD23(p = 0.015)和SRF(p = 0.024)。对于大多数这些基因,可以确定一个能正确分类大多数患者的临界值。
本研究鉴定的基因对LRB的敏感性和抗性的预测价值很有前景,应在更大的数据集中进行测试。